ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

University Hospital, Brest100 enrolled

Overview

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Advanced Hepatocellular Carcinoma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment * Child Pugh A and ECOG 0 or 1 * upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated * non eligible to receive a locoregional therpay or progressive after this kinf of treatment * with informed consent Exclusion Criteria: * refuse to participate * under legal protection * exclusion criteria from the tempory utilisation authorization

Outcomes

Primary Outcomes

predictive factor for progression-free survival

progression-free survival = time between treatment initiation and rediologic or clinical progression

Time frame: 12 months

Central Contacts

Pierre-Guillaume Poureau, MD

CONTACT

0298223740 pierre-guillaume.poureau@chu-brest.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.